These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16885346)

  • 21. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis.
    Foltz G; Yoon JG; Lee H; Ryken TC; Sibenaller Z; Ehrich M; Hood L; Madan A
    Oncogene; 2009 Jul; 28(29):2667-77. PubMed ID: 19465937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
    Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
    Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
    Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
    Zhao W; Soejima H; Higashimoto K; Nakagawachi T; Urano T; Kudo S; Matsukura S; Matsuo S; Joh K; Mukai T
    J Biochem; 2005 Mar; 137(3):431-40. PubMed ID: 15809347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.
    Yang Q; Liu S; Tian Y; Hasan C; Kersey D; Salwen HR; Chlenski A; Perlman EJ; Cohn SL
    Cancer Res; 2004 Jul; 64(13):4531-8. PubMed ID: 15231663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.
    Li X; Liu J; Zhou R; Huang S; Huang S; Chen XM
    Br J Haematol; 2010 Jan; 148(1):69-79. PubMed ID: 19807731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
    Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
    Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
    Costello JF; Berger MS; Huang HS; Cavenee WK
    Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
    Mühlisch J; Schwering A; Grotzer M; Vince GH; Roggendorf W; Hagemann C; Sörensen N; Rickert CH; Osada N; Jürgens H; Frühwald MC
    Oncogene; 2006 Feb; 25(7):1111-7. PubMed ID: 16186793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
    Liu Z; Marquez M; Nilsson S; Holmberg AR
    Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genetic and epigenetic analysis of NCX2/SLC8A2 at 19q13.3 in human gliomas.
    Qu M; Jiao H; Zhao J; Ren ZP; Smits A; Kere J; Nistér M
    Neuropathol Appl Neurobiol; 2010 Apr; 36(3):198-210. PubMed ID: 20132488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
    Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
    Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
    Magdinier F; Wolffe AP
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation and gene silencing in cancer.
    Baylin SB
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.
    Ying J; Li H; Seng TJ; Langford C; Srivastava G; Tsao SW; Putti T; Murray P; Chan AT; Tao Q
    Oncogene; 2006 Feb; 25(7):1070-80. PubMed ID: 16247458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.
    Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
    Wang LJ; Bai Y; Bao ZS; Chen Y; Yan ZH; Zhang W; Zhang QG
    Chin Med J (Engl); 2013; 126(11):2062-6. PubMed ID: 23769558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
    Yamashita S; Takahashi S; McDonell N; Watanabe N; Niwa T; Hosoya K; Tsujino Y; Shirai T; Ushijima T
    Cancer Res; 2008 Apr; 68(7):2112-21. PubMed ID: 18381416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.